SAN FRANCISCO, April 22, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs today announced that the United States Patent and Trademark Office has issued US Patent 8,703,907 covering controlled release of drugs from dendrimer conjugates over prolonged periods.
Help employers find you! Check out all the jobs and post your resume.
